RESONATE, RESONATE-2 and HELIOS: three major clinical trials in CLL research

Thomas Kipps, MD, PhD, from University of California, San Diego, CA, discusses the results from three clinical trials in this interview, all of which evaluate treatments for chronic lymphocytic leukemia (CLL). The first trial, RESONATE (NCT01578707), evaluated whether treatment with ibrutinib was superior to ofatumumab in treating patients with relapsed or refractory CLL. The second trial, RESONATE-2 (NCT01722487) was a Phase II study evaluating whether ibrutinib was superior to chlorambucil in treating CLL, and the third trial, HELIOS (NCT01611090), was a Phase III study evaluating the effectiveness of a bendamustine and ibrutinib combination in treating CLL. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video